Accuray ARAYAccuray ( NASDAQ:ARAY ) is currently the antithesis of a high-quality growth stock. It fails all elite screens: Gross Margins at 23.5% (vs 80% target), Negative ROE of -32%, and shrinking revenues (-12% YoY). The balance sheet is heavily leveraged with a Debt/Equity ratio near 2.9 and a distressing
Accuray Incorporated
No trades
No trades
Compare with Accuray Incorporated
−0.4064 USD
−49.19 M USD
401.95 M USD
114.15 M
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
Company info
Sector
Industry
CEO
Stephen R. la Neve
Website
Headquarters
Madison
Founded
1990
IPO date
Feb 8, 2007
ISIN
US0043971052
CUSIP
004397105
FIGI
BBG000QNRY51
Identifiers
ISIN US0043971052
Accuray, Inc. is a radiation therapy company, which engages in manufacturing medical equipment. It develops, manufactures, sells, and supports medical solutions. The company was founded by John R. Adler in 1990 and is headquartered in Madison, WI.
$ARAY the ascending triangle is now an upward channelWhat looks like a false breakout is turning into what could be an upward channel, Just shows why its better to scale in and out of positions. This way you scale in small and withstand any big swings and add on dips later. Still long and will add later.
$ARAY Attempting to break multiyear resistance. (Weekly Chart)Looking back at previous earnings announcements I don't think $ARAY has ever beat estimates for 3 or more quarters in a row. Currently it has beaten estimates for the past 4 consecutive qtrs. Its up 223% since its March lows and currently try to break a 5 year resistance level. Will be watching this
Accuray, Inc. Major Breakout Underway Accuray, Inc. is a radiation oncology company. It engages in the development, manufacture and sale of treatment solutions that includes cyberKnife and tomo therapy systems, designed to deliver radiosurgery, stereotactic body radiation therapy, intensity modulated radiation therapy, image-guided radi
See all ideas
Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently asked questions
The current price of ARAY is 0.2620 USD — it has decreased by −0.22% in the past 24 hours. Watch Accuray Incorporated stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Accuray Incorporated stocks are traded under the ticker ARAY.
ARAY stock has risen by 1.99% compared to the previous week, the month change is a −13.06% fall, over the last year Accuray Incorporated has showed a −82.65% decrease.
ARAY reached its all-time high on Feb 9, 2007 with the price of 31.0900 USD, and its all-time low was 0.2200 USD and was reached on Jul 28, 2026. View more price dynamics on ARAY chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
ARAY stock is 8.49% volatile and has beta coefficient of 1.75. Track Accuray Incorporated stock price on the chart and check out the list of the most volatile stocks — is Accuray Incorporated there?
Today Accuray Incorporated has the market capitalization of 31.29 M, it has decreased by −0.80% over the last week.
Yes, you can track Accuray Incorporated financials in yearly and quarterly reports right on TradingView.
Accuray Incorporated is going to release the next earnings report on Nov 11, 2026. Keep track of upcoming events with our Earnings Calendar.
ARAY earnings for the last quarter are −0.02 USD per share, whereas the estimation was −0.03 USD resulting in a 33.33% surprise. The estimated earnings for the next quarter are −0.07 USD per share. See more details about Accuray Incorporated earnings.
Accuray Incorporated revenue for the last quarter amounts to 100.92 M USD, despite the estimated figure of 105.30 M USD. In the next quarter, revenue is expected to reach 95.80 M USD.
ARAY net income for the last quarter is −1.94 M USD, while the quarter before that showed −11.80 M USD of net income which accounts for 0.00% change. Track more Accuray Incorporated financial stats to get the full picture.
No, ARAY doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Sep 9, 2026, the company has 809 employees. See our rating of the largest employees — is Accuray Incorporated on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Accuray Incorporated EBITDA is 2.03 M USD, and current EBITDA margin is 0.73%. See more stats in Accuray Incorporated financial statements.
Like other stocks, ARAY shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Accuray Incorporated stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Accuray Incorporated technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Accuray Incorporated stock shows the sell signal. See more of Accuray Incorporated technicals for a more comprehensive analysis.









